Pharmacological characterization of β-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle

Journal of Urology

Volumn 172, Issue 3, 2004, Pages 1155-1159

  Wanajo, Isao ^a   Tomiyama, Yoshitaka ^a   Yamazaki, Yoshinobu ^a   Kojima, Masami ^a   Shibata, Nobuo ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Muscle relaxations; Receptors, adrenergic, beta 2; Receptors, adrenergic, beta 3; Swine, miniature; Ureter

Indexed keywords

3 (2 ALLYLPHENOXY) 1 (1,2,3,4 TETRAHYDRONAPHTH 1 YLAMINO) 2 PROPANOL; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DESIPRAMINE; DOBUTAMINE; FORSKOLIN; ISOPRENALINE; NORADRENALIN; PHENTOLAMINE; POTASSIUM CHLORIDE; PROCATEROL; RECEPTOR SUBTYPE; SALBUTAMOL; SR 58894A; TERBUTALINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; SWINE; URETER; URETER PERISTALSIS;

EID: 4143142060     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000133557.39515.b6     Document Type: Article

References (20)

1. Weiss, R. M.: Physiology and pharmacology of the renal pelvis and ureter. In: Campbell's Urology, 7th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., vol. 1, sect. 5, chapt. 25, pp. 839-869, 1997
2. Tomiyama, Y., Hayakawa, K., Shinagawa, K., Akahane, M., Ajisawa, Y., Park, Y.-C. et al: Beta-adrenoceptor subtypes in the ureteral smooth muscle of rats, rabbits and dogs. Eur J Pharmacol, 352: 269, 1998
3. Park, Y.-C., Tomiyama, Y., Hayakawa, K., Akahane, M., Ajisawa, Y., Miyatake, R. et al: Existence of a β3-adrenoceptor and its functional role in the human ureter. J Urol, 164: 1364, 2000
4. Danuser, H., Weiss, R., Abel, D., Walter, B., Scholtysik, G., Mettler, D. et al: Systemic and topical drug administration in the pig ureter: effect of phosphodiesterase inhibitors α1, β and β2-adrenergic receptor agonists and antagonists on the frequency and amplitude of ureteral contractions. J Urol, 166: 714, 2001.
5. Chang, P. C., van der Krogt, J. A. and van Brummelen, P.: Demonstration of neuronal and extraneuronal uptake of circulating norepinephrine in the forearm. Hypertension 9: 647, 1987
6. Arunlakshana, O. and Schild, H. O.: Some quantitative uses of drug antagonists. Br J Pharmacol, 14: 48, 1959
7. Jenkinson, D. H., Barnard, E. A., Hoyer, D., Humphrey, P. P., Leff, P. and Shankley, N. P.: International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology Pharmacol Rev, 47: 255, 1995
8. Cullum, V. A., Farmer, J. B., Jack, D. and Levy, G. P.: Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br J Pharmacol, 35: 141, 1969
9. Persson, H. and Olsson, T.: Some pharmacological properties of terbutaline (INN), 1-(3,5-dihydroxyphenyl)-2-(T-butylamino)-ethanol. A new sympathomimetic beta-receptor-stimulating agent. Acta Med Scand Suppl, 512: 11, 1970
10. 3- adrenoceptor agonist (CL-316243). Drug Dev Res, 32: 69, 1994
11. Langin, D., Portillo, M. P., Saulnier-Blache, J. S. and Lafontan, M.: Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol, 199: 291, 1991
12. Kaumann, A. J. and Molenaar, P.: Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat. Br J Pharmacol, 118: 2085, 1996
13. Bilski, A. J., Halliday, S. E., Fitzgerald, J. D. and Wale, J. L.: The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol, 5: 430, 1983
14. Manara, L., Badone, D., Baroni, M., Boccardi, G., Cecchi, R., Croci, T. et al: Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol, 117: 435, 1996
15. Lands, A. M., Arnold, A., McAuliff, J. P., Luduena, F. P. and Brown, T. G., Jr.: Differentiation of receptor systems activated by sympathomimetic amines. Nature, 214: 597, 1967
16. McLaughlin, D. P. and MacDonald, A.: Evidence for the existence of 'atypical' beta-adrenoceptors (beta 3-adrenoceptors) mediating relaxation in the rat distal colon in vitro. Br J Pharmacol, 101: 569, 1990
17. Kobayashi, M., Takeda, K, Murata, S., Kojima, M., Akahane, M., Inoue, Y. et al: Pharmacological characterization of KUR-1246, a selective uterine relaxant. J Pharmacol Exp Ther, 297: 666, 2001
18. Kenakin, T.: Competitive antagonism. In: Pharmacologic Analysis of Drug-Receptor Interaction. New York: Raven Press, pp. 278-321, 1993
19. Blin, N., Nahmias, C., Drumare, M. F. and Strosberg, A. D.: Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol, 112: 911, 1994
20. Takeda, H., Yamazaki, Y., Akahane, M., Akahane, S., Miyata, H., Igawa, Y. et al: Characterization of beta-adrenoceptor sub-type in bladder smooth muscle in cynomolgus monkey. Jpn J Pharmacol, 88: 108, 2002